Your session is about to expire
← Back to Search
BI 754111 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a combination of two drugs to see if they can help the immune system fight cancer in adults with advanced solid tumors.
- Non-Small Cell Lung Cancer
- Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA granted clearance to BI 754111?
"Assessing the risk versus reward of BI 754111, our team gave it a rating of 1 due to limited clinical data supporting its safety and efficacy."
Are there any opportunities currently available to participate in this experiment?
"Clinicaltrials.gov does not indicate that this trial is presently open to recruitment, given its last update was on November 15th 2022 since first being posted 6/13/2017. There are 3,664 other trials actively sourcing participants at the moment though."
In what capacity is this clinical experiment being conducted across various facilities?
"As of right now, 8 sites are actively enrolling patients for this trial. Patients can find locations in Miami, Toronto and Hackensack as well as other cities across the United States. Therefore, to minimize travel needs during the study, it is essential to select a site that is close by."
Share this study with friends
Copy Link
Messenger